187 related articles for article (PubMed ID: 38571955)
1. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy-associated autoimmune hemolytic anemia.
Khan U; Ali F; Khurram MS; Zaka A; Hadid T
J Immunother Cancer; 2017; 5():15. PubMed ID: 28239468
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy-associated Autoimmune Hemolytic Anemia.
Hwang SR; Saliba AN; Wolanskyj-Spinner AP
Hematol Oncol Clin North Am; 2022 Apr; 36(2):365-380. PubMed ID: 35339260
[TBL] [Abstract][Full Text] [Related]
4. Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
Reddy SB; Possick JD; Kluger HM; Galan A; Han D
J Immunother; 2017 Oct; 40(8):307-311. PubMed ID: 28737620
[TBL] [Abstract][Full Text] [Related]
5. Auto-immune hemolytic anemia and hemophagocytic lymphohistiocytosis as immune-related adverse event in patients with metastatic melanoma and concurrent chronic lymphocytic leukemia: a case series and literature review.
Dirven I; Vander Mijnsbrugge AS; Mignon S; Tijtgat J; Kint N; Neyns B
Melanoma Res; 2023 Aug; 33(4):338-344. PubMed ID: 37114670
[TBL] [Abstract][Full Text] [Related]
6. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
7. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
Kähler KC; Hassel JC; Heinzerling L; Loquai C; Thoms KM; Ugurel S; Zimmer L; Gutzmer R;
J Dtsch Dermatol Ges; 2020 Jun; 18(6):582-609. PubMed ID: 32489011
[TBL] [Abstract][Full Text] [Related]
8. AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report.
Ni D; AlZahrani F; Smylie M
Case Rep Oncol; 2019; 12(2):456-465. PubMed ID: 31275137
[TBL] [Abstract][Full Text] [Related]
9. Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report.
Langan EA; Budner K; Zillikens D; Terheyden P
Medicine (Baltimore); 2021 Apr; 100(16):e25513. PubMed ID: 33879687
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune hemolytic anemia in hospitalized patients: 450 patients and their red blood cell transfusions.
Chen C; Wang L; Han B; Qin L; Ying B
Medicine (Baltimore); 2020 Jan; 99(2):e18739. PubMed ID: 31914091
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review.
Tanios GE; Doley PB; Munker R
Eur J Haematol; 2019 Feb; 102(2):157-162. PubMed ID: 30347480
[TBL] [Abstract][Full Text] [Related]
12. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
13. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
14. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
[TBL] [Abstract][Full Text] [Related]
15. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma.
Kong BY; Micklethwaite KP; Swaminathan S; Kefford RF; Carlino MS
Melanoma Res; 2016 Apr; 26(2):202-4. PubMed ID: 26795275
[TBL] [Abstract][Full Text] [Related]
16. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
17. Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.
Tao Y; Han J; Li Y
Invest New Drugs; 2022 Aug; 40(4):854-857. PubMed ID: 35503192
[TBL] [Abstract][Full Text] [Related]
18. Atypical anti-glomerular basement membrane glomerulonephritis in a patient with metastatic melanoma treated with mitogen-activated protein kinase and immune checkpoint inhibitors: a case report.
Kyriazis P; Tiwary A; Freeman J; Landry D; Braden G
J Med Case Rep; 2021 Apr; 15(1):186. PubMed ID: 33810799
[TBL] [Abstract][Full Text] [Related]
19. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in melanoma.
Carlino MS; Larkin J; Long GV
Lancet; 2021 Sep; 398(10304):1002-1014. PubMed ID: 34509219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]